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Summary Two assay procedures, an inhibition radioimmunoassay (Inhibition-RIA) and an
immunoradiometric assay (IRMA), were established for the detection of circulating tumour-associated Ca
antigen. There was a ggod correlation between results (r=0.987)'but the Inhibition-RIA was selected for
extended tests on human sera from patients with breast disease because of its greater ease and economy in
use. Circulating Ca antigen was not exclusive to malignancy and the level failed to discriminate between
patients with primary carcinoma and those with benign disease. Ca antigen was present in sera of 100 healthy
individuals (median 7.1 pgml-', range 1.8-24.4pgml)-', 39 patients with benign disease (median 9.9pgml- 1,
range 2.5-> 100pgml-') and in 67 patients with primary carcinoma (median 1.0pgml-', range 3.8-
>100ugml-'). Elevated Ca antigen levels were found in 50% of patients with metastatic spread (median
30.7pgmlP', range 8.2->l 00gmlP') and in some patients with primary disease but further studies are
needed to determine the prognostic significance. Immunochemical studies confirmed that Ca antigen is a
normal serum product but its function is unclear.
There is considerable interest in non-invasive
techniques for the early detection of breast
carcinoma. Elevated serum levels of several markers
have been reported in patients with breast disease
but the sensitivity and specificity of detection have
been inadequate for early diagnosis (Coombes et
al., 1982; Waalkes et al., 1984; Wang et al., 1984).
Polyclonal antibodies have been almost exclusively
used in assays for circulating tumour-associated
antigens. It is conceivable that monoclonal
antibodies of restricted epitope specificity may
improve diagnostic discrimination. Monoclonal Ca 1
antibody which defines a mucin type glycoprotein
has been reported to react selectively in immuno-
histochemical studies with malignant lesions
taken from a variety of tissues (McGee et al.,
1982; Woods et al., 1982), although more recent
studies have shown that reactivity is not exclusive
to malignant lesions of the'breast (Simpson et al.,
1983; Beckford & Chantler, 1984; Beckford et al.,
1985).
This work was undertaken to establish a simple
assay for detection of Ca antigen in serum and to
determine whether measurement of circulating Ca
antigen would be helpful in discriminating between
benign and malignant breast disease.
Materials and methods
Serum samples
These were obtained from 88 normal blood donors,
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12 individuals with recent viral infection (rubella),
39 patients with benign and 93 patients with
malignant breast disease of whom 26 were known
to have metastases at the time of sampling. Samples
were stored at -20°C prior to use. Seventy-seven
of the 132 patients sera were collected during 1974-
75, the remainder within 12 months of assay.
Antigen preparations
Crude Ca antigen was prepared from HEp2 cells
(-5 x 106) by centrifugation, followed by washing
in PBS (2 x) and extraction in 1% Triton X-100
and 10mM Tris HCI pH8 (1:lv/v) for lh at 4°C.
After centrifugation at 10,000g for 30min, 1% (w/v)
sodium deoxycholate was added to the supernatant.
Extracts of control antigen were similarly derived
from a lymphoblastoid cell line (Namalwa), known
to be free of Ca antigen.
A lyophilised preparation of purified Ca antigen
(donated by Dr M.E. Bramwell, Sir William Dunn
School of Pathology, Oxford) was reconstituted in
10mM PBS, pH 7.6, to give a nominal concen-
tration of 1 Mgml-'. The mass units assigned to this
preparation reflect the mass of the protein in the
antigen as assessed by amino acid analysis.
Monoclonal antibodies
1251 Ca 1: The immunoglobulin fraction was
prepared from Ca 1 (IgM) ascitic fluid (supplied by
Dr F. Shand, Wellcome Research Laboratories) by
affinity chromatography on a Sepharose 4B anti-
mouse IgM immunoadsorbent column and elution
with acid. The eluted peak was dialysed against
PBS and labelled with 125NaI by the lacto-
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peroxidase procedure. Partially purified IgM
preparations for coating the solid phase were
obtained from Ca 1 ascitic fluid by cryo-
precipitation. Control IgM preparations were
derived by analogous procedures from ascitic fluid
containing an IgM anti-meningococcal monoclonal
antibody (supplied by Dr M. Mclllmurray,
Wellcome Research Laboratories).
Assay procedures
Inhibition radioimmunoassay (Inhibition-RIA) Poly-
vinyl microtitre wells were coated with crude Ca
antigen (200p1, diluted 1: 1,000 in PBS) and incubated
for 1 h at 37°C, followed by overnight at 4°C.
One hundred and twenty-five p1 of each serum
sample diluted 1:5 and 1:20 in PBS, was added
to an equal volume of 1251 Ca 1 antibody
(250,000c.p.m.) in 6% BSA/PBS and incubated
for 2h at room temperature (RT). The serum/tracer
mixture (100,l containing 100,000c.p.m.) was
added, in duplicate, to antigen and control antigen
coated wells previously washed with 3% BSA/PBS
(x3) and incubated for 2h at RT. After washing
the wells (0.05% Tween/PBS x 3) the bound activity
was counted. A standard curve of crude Ca antigen
prepared in 20% normal mouse serum in PBS
(previously calibrated against the purified Ca antigen
preparation) was included in each assay and used to
calculate Ca antigen levels in sera.
Immunoradiometric assay (IRMA) Polystyrene
tubes (6cm x 1 cm) were coated with IgM
preparations (200pl, 15 gml-' PBS) derived from
Ca 1 or control IgM ascitic fluid at 4°C overnight.
After washing with PBS (2mlx3), 100p1 of serum
was added to duplicate tubes and left at 4°C
overnight. After a further wash cycle, 100p1 of 1251
Ca 1 (100,000c.p.m.) diluted in 3% BSA/PBS
containing 10% normal mouse serum, was added.
The tubes were incubated at RT for 4h, washed
with PBS (2 x 3ml) and counted. The results were
read from the standard curve as described for the
Inhibition RIA.
Immunohistochemistry The presence of Ca antigen
in paraffin wax embedded tissue sections taken
from benign and malignant lesions was detected by
the indirect immunoenzyme procedure described by
Beckford & Chantler (1984) with the exception that
alkaline phosphatase was substituted as label
(Foster et al., 1982).
Identification of Ca antigen in serum Ca antigen
was separated from serum by affinity chromato-
graphy using a modification of the procedure
reported by Ashall et al (1982). Fifteen ml of
serum, dialysed against PBS was applied to an
immunoadsorbent column (2 x 7cm) of Sepharose
4B-Ca 1. The bound fraction, containing Ca antigen,
was eluted with 3M sodium thiocyanate (pH7.6)
in PBS, dialysed and concentrated by lyophilisation.
The sample constituents were separated by SDS poly-
acrylamide gel electrophoresis (SDS-PAGE) and the
presence of Ca antigen was detected by autoradio-
graphy or indirect immunofluorescence. Each
sample was reconstituted with distilled water (100pl)
and a 30,ul aliquot was reduced by boiling in
2% P-mercaptoethanol and 2% sodium dodecyl
sulphate (SDS) for 5min and applied to 5% poly-
acrylamide gels (Laemeli, 1970) which were electro-
phoresed for 5h at 40mA. Crude Ca antigen extract
was treated in the same way and included in each
run. Localisation on the gels was performed by
incubating with 1251 wheat germ lectin
(overnight/RT) followed by dehydration and
autoradiography (Ashall et al., 1982). Alternatively
the separated components were transferred to
nitrocellulose (Towbin et al., 1979) before staining
with Ca 1 ascitic fluid (1:30 in 3% BSA/PBS)
overnight at RT followed by FITC labelled sheep
anti-mouse IgM (1:20 in PBS) for 0.5h at RT.
Fluorescence was detected using an excitation
wavelength of 366nm.
Results
Comparison ofinhibition radioimmunoassay
(Inhibition-RIA) and immunoradiometric (IRMA)
assay
Two assay procedures, the Inhibition-RIA and
Immunoradiometric (IRMA) assay, were
established and assay specificity, sensitivity and
correlation determined.
The dose response curves obtained with dilutions
of Ca antigen are shown in Figure 1 together
-6
oi
+1
6.
6
c
E
C
0
.0
_C
6000
5000
4000
3000
2000
1000
0
3000
U, n
+1
2000
a)
1000 E
cc
0
50 100 250 500 1000 2000 5000
Ca antigen ng ml-
Figure 1 Standard curves in the Inhibition-RIA (0)
and Immunoradiometric assay (U) for Ca antigen.
Mean+s.d. of zero standard (shaded area).
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with the inter-assay variation obtained with
quadruplicate tests performed on three occasions.
The sensitivity of the Inhibition-RIA was slightly
greater than IRMA, the lower limit of Ca detection
lay between 100-250 ngml-l and 250-500 ngml-l
respectively. The inter-assay variation, determined
by assaying aliquots of 2 serum pools (mean values
7.1 and 13.9gml-P 1) in successive assays was
18.0% (n=14) and 10.6% (n = 15) respectively. The
intra-assay variation for 24 samples assayed in
duplicate was 9.8%. The specificity of assay
responses was confirmed by using an extract of
Namalwa (lymphoblastoid) cells as control antigen
and IgM monoclonal antibody of unrelated
specificity (anti-meningococcus) as control antibody.
No significant binding was obtained when control
antigen was used for coating the solid phase or
iodinated control antibody as label in the
Inhibition-RIA. In addition, when control antigen
was used as sample, inhibition of 125I Ca 1 specific
binding did not occur: In the IRMA, the level of
binding with Ca samples was similar to background
when either control antibody was substituted for
Ca 1 on the solid phase or control antigen was used
as sample.
Twenty-eight serum samples covering a range of
Ca levels were tested by both procedures. A good
correlation was seen between the Ca values in the
two assays (r =0.987, P<0.0001). The Inhibition-
RIA was selected for subsequent tests because of its
greater speed, economy of sample requirement,
increased sensitivity and ease of use.
Ca activity in serum samples
In a preliminary study, serial dilutions of serum
samples taken from normal subjects and from
patients with benign and malignant breast disease
were tested in the Inhibition-RIA. The dose
response curves of representative samples of each
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Figure 2 Titration of serum samples in the Inhibition-
RIA from normal subjects (0), patients with benign
(U) and malignant (-) breast disease in the Inhibition-
RIA.
group are shown in Figure 2. Whilst there was a
considerable overlap between the curves obtained
with individual samples the extent of inhibition,
reflecting the amount of Ca activity present, was
greatest with sera taken from patients with
carcinoma.
An extended analysis was performed on the levels
of Ca antigen in sera from 93 patients with
malignant and 39 with benign breast disease and
from 100 normal subjects, which included samples
from 12 individuals with acute viral infection. All
samples gave some reactivity in the assay. The
range of values obtained in each group and the
distribution are shown in Table I and Figure 3. A
wide range of values was obtained within each
group and the possibility that these were due to
technical parameters such as poor assay
Table I Range of Ca antigen levels in sera from normal subjects and from patients with
benign and malignant breast disease.
P value P value
Range (relative (relative
Group n (ggml ) Median to normals) to benign)
1. Normal subjects:
a. Blood donors 88 2.4-24.4 7.1
b. Acute rubella 12 1.8-16.1
2. Benign disease 39 2.5->100 9.9 0.017
3. Malignant disease
a. Primary 67 3.8->100 11.0 <0.001 0.26
b. Metastases 26 8.2->100 30.7 <0.001 <0.001
Statistical analysis: Kruska Wallis one way analysis of variance and Mann-Whitney
U-Test.
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presence of Ca antigen. Ca antigen was found to be
present in >50% of the carcinoma cells in 5 out of
6 patients with primary breast disease, 2 patients
with metastases and 4 out of 11 patients with
benign breast tumours. There was no clear
correlation between the presence of antigen in the
tissue sections and the level of circulating Ca
antigen in these patients.
* It
-0- ~~~~~T
_ I
Normals Benign Primary Metastases
carcinoma
n = 100 n = 39 n = 67 n = 26
Figure 3 Levels of Ca antigen in serum samples from
patients with benign and malignant breast disease and
normal subjects. ( 0) median.
reproducibility or serum storage conditions was
excluded.
The range of values for the group of normal
subjects was 1.8-24.4ugml-1 with a median value
of 7.1. Five sera within the benign group (12.8%)
had Ca levels greater than the control group 25.1,
26.6, 28.7, 34.1, >100) but only one was
significantly elevated. This patient had
endometriosis but no evidence of malignancy. The
proportion of primary carcinoma patients showing
elevated Ca levels was similar to that found in the
benign disease group (8/67=11.9%). The median
values 9.9 and 11.0 in the benign and primary
carcinoma groups were not significantly different
(P=0.26) but three patients in the latter group had
highly elevated levels (58, 65.5, >100) and one of
these relapsed at 2 years (>100). Other patients
with known early relapse, however, had Ca values
within the normal range. Although there was an
overlap between the Ca values obtained in each
group, the median Ca value of samples taken from
patients with metastases differed significantly from
that of the control and benign disease groups
(P= <0.001). This was due to the high proportion
of samples (13/26, 50%) with significantly elevated
activity. Unfortunately it was not possible to
determine whether testing of sequential samples
from individual patients would be of prognostic
value.
These results show that measurement of
circulating Ca fails to discriminate between
individuals with primary carcinoma of the breast
and non-malignant conditions.
Correlation between circulating and tissue Ca antigen
Sections of cancer (8 patients) and benign breast
tumour (11 patients) were examined for the
Identification ofCa antigen in serum
Low levels of Ca activity were found in all normal
serum samples. In order to confirm that this was
due to the presence of Ca antigen, studies were
undertaken to purify Ca antigen from three normal
sera. Serum samples were partially purified by
affinity chromatography on a Sepharose 4B-Ca 1.
Unbound material, present in the void volume and
specifically bound components, eluted with sodium
thiocyanate, were tested in the Inhibition-RIA. The
major proportion of the original activity was
recovered in the eluate. Components in this fraction
were separated by SDS polyacrylamide gel
electrophoresis and the presence of Ca was
demonstrated by 121I wheat germ lectin or indirect
immunofluorescence. The autoradiograph obtained
after treating the gels with 1251 wheat germ lectin
showed that a high mol. wt component, analogous
to that seen in the gel containing HEp2 extract and
exhibiting the properties of Ca antigen (Bramwell et
al., 1983), was present in samples separated from
normal serum (Figure 4). Immunofluorescence
failed to give conclusive results with material
isolated from normal sera but stained the 2 major
high mol. wt components in the HEp2 extract
which bound 1251I wheat germ lectin. The results
show that at least one of the high mol. wt
components present in Ca antigen is present
in normal serum. Our failure to demonstrate
Ca in preparations from normal serum by
immunofluorescence is likely to be due to
inadequate sensitivity.
Discussion
This study shows that the presence of Ca antigen in
human serum is not exclusive to malignancy and
that the level of circulating Ca antigen fails to
discriminate between primary carcinoma and
non-malignant conditions of the breast. This
observation is in agreement with the general
conclusions reached in recent reviews dealing with a
range of biological markers used in breast disease
(Coombes et al., 1982; Waalkes et al., 1984).
Although the presence of Ca antigen in serum had
no diagnostic significance, 50% of patients with
metastatic spread had significantly elevated levels.
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Figure 4 Autoradiograph of SDS-PAGE of (a) HEp2
cell extract and (b) material derived from normal
serum localised with 125I wheat germ lectin.
The possibility that measurement of Ca levels in
sequential serum samples may be of prognostic
value in individual patients cannot be excluded.
Similar results have been reported in a study using
a polyclonal antibody in which the circulating levels
of human mammary epithelial antigens (HME-Ags)
in patients with breast disease were investigated
(Ceriani et al., 1982). It has been suggested that the
use of monoclonal antibodies might increase the
diagnostic significance of potential tumour markers
but this does not appear to be the case for Ca
antigen.
Our failure to obtain a quantitative difference
between levels of Ca antigen in benign and
malignant disease is not unexpected as recent
immunohistochemical studies have shown that Ca
antigen is present in a high proportion of benign
breast lesions (Simpson et al., 1983; Beckford
et al., 1984). Comparison of circulating and
tissue Ca antigen in individual patients performed
in this study showed that Ca antigen was present in
almost all' tissues irrespective of the histological
classification and that an extensive tissue
distribution was not associated with elevated levels
of circulating antigen. In this context, it is
interesting to note that circulating human milk fat
globule antigens were not detected in sera from
normal subjects and patients with benign breast
disease by Ceriani et al. (1982) despite the presence
of tissue antigen in benign lesions by immuno-
histochemical tests (Ceriani et al., 1979).
A significant feature of this study was the
observation that Ca antigen was present in all
serum samples tested. The specificity of our assay
was confirmed by the use of control antigen and
antibody but definitive evidence that the active
component in serum was Ca antigen was obtained
by purification and immunochemical analysis.
Comparison with HEp2 extracts showed con-
clusively that the active component in normal
sera was analogous to one of the 2 high mol. wt
components of Ca antigen (Bramwell et al., 1983).
The absence of the second component is thought to
be a reflection of the known polymorphism of the
antigen (M. Bramwell, personal communication).
Our studies show that Ca antigen is a normal
serum product but its function has yet to be
determined. The detection of circulating Ca antigen
is not of diagnostic significance in breast cancer
and limited analysis suggest that elevated values in
primary carcinoma patients are not associated with
early relapse (results not given). Further work to
determine the prognostic value of circulating Ca
antigen in breast disease and to investigate the
applicability of our conclusions to other diseased
organs is in progress.
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